Chief Business Officer at GPCR Therapeutics, Inc. | 20+ years of dealmaking from all sides of the table
🎉 Huge congratulations to Orum Therapeutics for their deal yesterday! Vertex bolts on Orum's Degrader-Antibody Conjugate(DAC) conditioning agents to ImmunoGen's ADC conditioner, acquired in March 2023. But what drives Vertex to explore novel conditioner candidates? Traditional conditioning agents are poorly tolerated and have posed significant challenges for Hematopoietic Stem Cell (#HSC) Cell and Gene Therapies (CGT), such as Vertex's Casgevy. These hurdles are now being addressed by novel, less aggressive conditioners, as above. For instance, companies like Actinium Pharmaceuticals are also advancing novel conditioning agents in this space. Thus, improved conditioning agents will play a crucial role in expanding the application of HSC CGT. Another critical challenge in HSC CGT is effective #mobilization. Emerging CGTs often require a higher yield of HSCs than conventional HSC transplantation in cancer. When it comes to in vivo approaches, having more HSCs available in peripheral blood will be critical since ex vivo collection and engineering are not feasible. Thus, there is a growing demand for enhanced HSC mobilizers in this evolving field. Here comes #GPC201, a potential best/fastest-in-class HSC mobilizer currently in phase 2 clinical trials in the US. It is demonstrating superior features for HSC transplantation in multiple myeloma. As the universe of various CGT pipelines expands rapidly, GPC201 is poised to showcase its full potential. I eagerly anticipate the transformative impact of pairing GPC201 with novel conditioning agents to enhance patients' HSC transplantation experiences. Curious about GPC201? 👉👉👉 GPCR Therapeutics
We’re excited to announce a global, multi-target license and option agreement with Vertex Pharmaceuticals for the use of Orum’s Dual-Precision Targeted Protein Degradation (TPD²®) technology to develop novel degrader-antibody conjugates as targeted conditioning agents for use with gene editing. Read the release here: https://lnkd.in/gyguMg8v #TPD #targetedproteindegradation #ADC #ADCs #antibodydrugconjugates
